Mitral Valve Repair With the Chord-X System: A Long Term Evaluation

Inclusion Criteria: * Patient provided written Informed Consent * Patient underwent mitral valve procedure (defined as mitral valve surgical intervention via endoscopic, mini thoracotomy, or full sternotomy approach, including mitral annuloplasty with a ring, resection of mitral valve leaflets, and replacement of mitral chordae tendineae) using the Chord-X System as clinically indicated (i.e. not off-label) by Principal Investigator at research site * Patient's Chord-X System implant occurred no earlier than January 1, 2022 * Patient is able and willing to participate in follow-up visits for the duration of the study (i.e. through 10 years post-op) Exclusion Criteria: * Patient was implanted with the Chord-X System off-label * Patient was implanted with the Chord-X System prior to January 1, 2022 * Patient has had previous mitral valve surgery * Patient underwent a multi valve repair procedure * Patient with an ejection fraction ≤ 50% at baseline * Patient underwent concomitant surgical procedures (except for maze procedure, PFO or LAA closure) at time of mitral repair procedure * Patient whose mitral valve procedure was performed as part of an emergency surgery (defined as a time period from diagnosis to surgery of ≤ 48 hours) * Patient with persistent or permanent atrial fibrillation * Patient with active or a history of endocarditis * Patient with congenital heart disease